Ten Investors to Buy Stake in Fosun Pharmaceutical Unit

MT Newswires Live08-28

Ten investors plan to acquire a 0.12% stake in Shanghai Fosun Pharmaceutical's (HKG:2196, SHA:600196) subsidiary Fosun Antekin (Chengdu) Biopharmaceutical, according to a Tuesday disclosure on the Shanghai Stock Exchange.

The investors include the pharmaceutical company's executive directors Wu Yifang, Wang Kexin, Guan Xiaohui and Wen Deyong. They plan to buy 968,700 yuan of Fosun Antekin's registered capital at 68.65 yuan apiece.

Additionally, Fosun Antekin will issue additional registered capital of 32 million yuan, representing 4% of its share capital, to establish an incentive platform, Fosun Pharma said.

Price (HKD): $12.36, Change: $-0.060, Percent Change: -0.48%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2462108871?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-08-28 11:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2462108871","market":"sg","top_or_hot":-1,"title":"Ten Investors to Buy Stake in Fosun Pharmaceutical Unit","media":"MT Newswires Live","content":"<html><body><p> Ten investors plan to acquire a 0.12% stake in Shanghai Fosun Pharmaceutical's (HKG:2196, SHA:600196) subsidiary Fosun Antekin (Chengdu) Biopharmaceutical, according to a Tuesday disclosure on the Shanghai Stock Exchange.</p><p>The investors include the pharmaceutical company's executive directors Wu Yifang, Wang Kexin, Guan Xiaohui and Wen Deyong. They plan to buy 968,700 yuan of Fosun Antekin's registered capital at 68.65 yuan apiece.</p><p>Additionally, Fosun Antekin will issue additional registered capital of 32 million yuan, representing 4% of its share capital, to establish an incentive platform, Fosun Pharma said.</p><p>Price (HKD): $12.36, Change: $-0.060, Percent Change: -0.48%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ten Investors to Buy Stake in Fosun Pharmaceutical Unit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTen Investors to Buy Stake in Fosun Pharmaceutical Unit\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-28 11:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ten investors plan to acquire a 0.12% stake in Shanghai Fosun Pharmaceutical's (HKG:2196, SHA:600196) subsidiary Fosun Antekin (Chengdu) Biopharmaceutical, according to a Tuesday disclosure on the ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02196","symbol_name":"复星医药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2462108871","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2462108871","pubTimestamp":1724816019,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Ten investors plan to acquire a 0.12% stake in Shanghai Fosun Pharmaceutical's (HKG:2196, SHA:600196) subsidiary Fosun Antekin (Chengdu) Biopharmaceutical, according to a Tuesday disclosure on the Sha","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","02196":"复星医药","BK4211":"区域性银行","BK0012":"证金概念","BK0096":"民营医院","BK0060":"抗癌","00656":"复星国际","BK0196":"行业龙头","BK4526":"热门中概股","BK4588":"碎股","HKD":"尚乘数科","BK1191":"制药","BK0183":"MSCI概念","BK0239":"医药制造","BK0175":"白马股","BK1593":"医美概念股","BK4585":"ETF&股票定投概念","BK0028":"国家队","BK1230":"工业集团企业","BK0188":"融资融券","BK0187":"一线龙头","BK4023":"应用软件","ISBC":"投资者银行","BK1515":"抗疫概念"},"translate_title":"十名投资者将购买复星医药部门的股份","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":0.9,"00656":1,"ISBC":1,"HKD":1,"02196":0.9},"content_text":"Ten investors plan to acquire a 0.12% stake in Shanghai Fosun Pharmaceutical's (HKG:2196, SHA:600196) subsidiary Fosun Antekin (Chengdu) Biopharmaceutical, according to a Tuesday disclosure on the Shanghai Stock Exchange.The investors include the pharmaceutical company's executive directors Wu Yifang, Wang Kexin, Guan Xiaohui and Wen Deyong. They plan to buy 968,700 yuan of Fosun Antekin's registered capital at 68.65 yuan apiece.Additionally, Fosun Antekin will issue additional registered capital of 32 million yuan, representing 4% of its share capital, to establish an incentive platform, Fosun Pharma said.Price (HKD): $12.36, Change: $-0.060, Percent Change: -0.48%","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2462108871"}